Table 1.
Nrf2 Activating Agents Reported to Offer Clinical Benefits in COVID-19 Patients.
| No | Nrf2 Activating Agent Name | Reference |
|---|---|---|
| 1. | Dimethyl fumarate | [72] |
| 2. | Ozone-oxygen gas mixtures | [73], [74] |
| 3. | Methylene blue | [75], [76] |
| 4. | Low-level laser/photobiomodulation | [77], [78] |
| 5. | Azithromycin | [79], [80] |
| 6. | Chloroquine | [80], [81] |
| 7. | Dexamethasone | [14], [82] |
| 8. | Naringenin | [83], [84] |
| 9. | Quercitin | [85], [86] |
| 10. | Sulforaphane | https://www.dundee.ac.uk/stories/clinical-trial-potential-covid-19-treatment; [32] |
| 11. | Sulforadex (SFX-01) | [32] |
| 12. | Bardoxolone methyl | [32] |
| 13. | Omaveloxolone (RTA-408) | [32] |